As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

Hospital groups raise issues with 340B rebate pilot program citing cash flow, administrative costs, and unclear rebate denials risks.

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

The past year has seen a great deal of controversy surrounding the 340B Drug Pricing Program, in which drug manufacturers make prescription drugs available to safety net healthcare providers at deeply ...

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

The 340B program is a prime example of public policy gone wrong. The original intent of the program was good, but based on current results, the program is flawed and is in desperate need of reform.

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

While more than 2,900 U.S. hospitals hold tax-exempt status as nonprofits, critics argue they have undergone a “mission drift ...